AURORA, Colo. -- Atosiban, an oxytocin receptor antagonist available in Europe, was not superior to placebo in improving neonatal outcomes for threatened preterm birth between 30 and 34 weeks' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback